VIVEVE MEDICAL, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0002 USD | -33.33% |
|
-33.33% | 0.00% |
| 2023 | InMode Ltd. acquired Intellectual Property Assets of Viveve Medical Inc. | CI |
| 2023 | Viveve Medical, Inc.(OTCPK:VIVE) dropped from S&P TMI Index | CI |
Valuation
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 54.84 | 96.55 | 47.1 | 5.07 | 10.21 | 12.09 |
| Enterprise Value (EV) 1 | 56.38 | 104.8 | 48.1 | -3.855 | 9.675 | -1.399 |
| P/E ratio | - | -2.35 x | -0.65 x | -0.04 x | -0.28 x | -0.43 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 7.68 x | 6.32 x | 2.54 x | 0.77 x | 1.86 x | 1.88 x |
| EV / Revenue | 7.9 x | 6.85 x | 2.6 x | -0.59 x | 1.77 x | -0.22 x |
| EV / EBITDA | -3.03 x | -3.15 x | -1.09 x | 0.13 x | -0.56 x | 0.07 x |
| EV / FCF | -4.93 x | -4.6 x | -1.68 x | 0.19 x | -1.04 x | 0.21 x |
| FCF Yield | -20.3% | -21.7% | -59.4% | 523% | -95.8% | 465% |
| Price to Book | -136 x | -37.3 x | 9.91 x | 0.54 x | 1.46 x | 0.8 x |
| Nbr of stocks (in thousands) | 10.6 | 19.4 | 44.9 | 402 | 2,171 | 10,603 |
| Reference price 2 | 5,150 | 4,970 | 1,050 | 12.60 | 4.700 | 1.140 |
| Announcement Date | 2/16/17 | 3/16/18 | 3/15/19 | 3/19/20 | 3/18/21 | 3/17/22 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Net sales 1 | 7.141 | 15.29 | 18.52 | 6.567 | 5.479 | 6.426 |
| EBITDA 1 | -18.59 | -33.28 | -44.18 | -28.76 | -17.2 | -20.43 |
| EBIT 1 | -18.7 | -33.73 | -44.96 | -29.94 | -18.5 | -21.55 |
| Operating Margin | -261.92% | -220.63% | -242.83% | -455.87% | -337.56% | -335.4% |
| Earnings before Tax (EBT) 1 | -20.11 | -36.96 | -49.32 | -41.9 | -21.53 | -21.77 |
| Net income 1 | -20.11 | -36.96 | -49.98 | -42.53 | -21.92 | -22.03 |
| Net margin | -281.63% | -241.75% | -269.92% | -647.57% | -399.98% | -342.78% |
| EPS | - | -2,112 | -1,609 | -343.9 | -16.56 | -2.648 |
| Free Cash Flow 1 | -11.44 | -22.75 | -28.58 | -20.16 | -9.273 | -6.512 |
| FCF margin | -160.15% | -148.83% | -154.35% | -306.97% | -169.25% | -101.33% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/16/17 | 3/16/18 | 3/15/19 | 3/19/20 | 3/18/21 | 3/17/22 |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 Q2 | 2020 Q3 | 2020 Q4 | 2021 Q1 | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.704 | 1.524 | 1.947 | 1.45 | 1.654 | 1.616 | 1.706 | 1.641 | 1.795 | 1.684 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -4.941 | -3.404 | -4.323 | -5.129 | -4.945 | -5.492 | -5.987 | -5.473 | -5.02 | -4.662 |
| Operating Margin | -701.85% | -223.36% | -222.03% | -353.72% | -298.97% | -339.85% | -350.94% | -333.52% | -279.67% | -276.84% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | -8.136 | -4.788 | -5.84 | -6.91 | -5.169 | -7.048 | -7.556 | -7.152 | -7.104 | -6.323 |
| Net margin | -1,155.68% | -314.17% | -299.95% | -476.55% | -312.52% | -436.14% | -442.91% | -435.83% | -395.77% | -375.48% |
| EPS 2 | -5.700 | -2.600 | -1.860 | -0.8000 | -0.4900 | -0.6700 | -0.7200 | -0.6700 | -0.6700 | -0.5900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/13/20 | 11/12/20 | 3/18/21 | 5/13/21 | 8/12/21 | 11/11/21 | 3/17/22 | 5/12/22 | 8/11/22 | 11/10/22 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 1.54 | 8.22 | 1.01 | - | - | - |
| Net Cash position 1 | - | - | - | 8.93 | 0.53 | 13.5 |
| Leverage (Debt/EBITDA) | -0.083 x | -0.2469 x | -0.0227 x | - | - | - |
| Free Cash Flow 1 | -11.4 | -22.8 | -28.6 | -20.2 | -9.27 | -6.51 |
| ROE (net income / shareholders' equity) | -1,139% | 2,460% | -4,267% | -391% | -183% | -198% |
| ROA (Net income/ Total Assets) | -91.1% | -83.3% | -67.8% | -50.7% | -53% | -63.3% |
| Assets 1 | 22.07 | 44.38 | 73.73 | 83.88 | 41.34 | 34.78 |
| Book Value Per Share 2 | -38.00 | -133.0 | 106.0 | 23.30 | 3.210 | 1.420 |
| Cash Flow per Share 2 | 758.0 | 1,063 | 637.0 | 18.80 | 3.000 | 1.800 |
| Capex 1 | 0.26 | 0.91 | 2.14 | 1.09 | 0.78 | 0.46 |
| Capex / Sales | 3.58% | 5.92% | 11.57% | 16.55% | 14.25% | 7.1% |
| Announcement Date | 2/16/17 | 3/16/18 | 3/15/19 | 3/19/20 | 3/18/21 | 3/17/22 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 2.14K | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B | |
| +26.76% | 32.03B |
- Stock Market
- Equities
- VIVE Stock
- Financials Viveve Medical, Inc.
